Paper37566005
Ectodomain Shedding by ADAM17 Increases the Release of Soluble CD40 from Human Endothelial Cells under Pro-Inflammatory Conditions.
Klersy A and 5 others. Cells, 2023. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Ectodomain Shedding by ADAM17 Increases the Release of Soluble CD40 from Human Endothelial Cells under Pro-Inflammatory Conditions. Papers, record 37566005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37566005
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Ectodomain Shedding by ADAM17 Increases the Release of Soluble CD40 from Human Endothelial Cells under Pro-Inflammatory Conditions.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| ADAM17 Protein | Major topic |
| CD40 Antigens | Major topic |
| Humans | |
| C-Reactive Protein | |
| CD40 Ligand | |
| Human Umbilical Vein Endothelial Cells | |
| Interleukin-6 | |
| Tumor Necrosis Factor-alpha |
Source PubMed
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33579029 | Strategies to Target ADAM17 in Disease: From its Discovery to the iRhom Revolution. | Molecules | 2021 | https://conductscience.org/library/papers/33579029 | PubMed |
| 2 | 30065258 | Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. | Nat Rev Cardiol | 2018 | https://conductscience.org/library/papers/30065258 | PubMed |
| 3 | 25687272 | A score including ADAM17 substrates correlates to recurring cardiovascular event in subjects with atherosclerosis. | Atherosclerosis | 2015 | https://conductscience.org/library/papers/25687272 | PubMed |
| 4 | 18849075 | Characterization of natural human antagonistic soluble CD40 isoforms produced through alternative splicing. | Mol Immunol | 2008 | https://conductscience.org/library/papers/18849075 | PubMed |
| 5 | 31558283 | Association of soluble CD40L with short-term and long-term cardiovascular and all-cause mortality: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. | Atherosclerosis | 2019 | https://conductscience.org/library/papers/31558283 | PubMed |
| 6 | 11172023 | Regulation of CD40 function by its isoforms generated through alternative splicing. | Proc Natl Acad Sci U S A | 2001 | https://conductscience.org/library/papers/11172023 | PubMed |
| 7 | 28705384 | The shedding protease ADAM17: Physiology and pathophysiology. | Biochim Biophys Acta Mol Cell Res | 2017 | https://conductscience.org/library/papers/28705384 | PubMed |
| 8 | 23433179 | CD154: the atherosclerotic risk factor in rheumatoid arthritis? | Arthritis Res Ther | 2013 | https://conductscience.org/library/papers/23433179 | PubMed |
| 9 | 11328886 | A new mathematical model for relative quantification in real-time RT-PCR. | Nucleic Acids Res | 2001 | https://conductscience.org/library/papers/11328886 | PubMed |
| 10 | 17295440 | Increased serum soluble CD40 levels in patients with systemic sclerosis. | J Rheumatol | 2007 | https://conductscience.org/library/papers/17295440 | PubMed |
| 11 | 31373353 | Functional association of a CD40 gene single-nucleotide polymorphism with the pathogenesis of coronary heart disease. | Cardiovasc Res | 2020 | https://conductscience.org/library/papers/31373353 | PubMed |
| 12 | 19426221 | Molecular mechanism and function of CD40/CD40L engagement in the immune system. | Immunol Rev | 2009 | https://conductscience.org/library/papers/19426221 | PubMed |
| 13 | 31570051 | Association between CD40 polymorphisms and systemic lupus erythematosus and correlation between soluble CD40 and CD40 ligand levels in the disease: a meta-analysis. | Lupus | 2019 | https://conductscience.org/library/papers/31570051 | PubMed |
| 14 | 33309175 | Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. | J Am Coll Cardiol | 2020 | https://conductscience.org/library/papers/33309175 | PubMed |
| 15 | 9102169 | Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. | Arterioscler Thromb Vasc Biol | 1997 | https://conductscience.org/library/papers/9102169 | PubMed |
| 16 | 19258599 | Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases. | Blood | 2009 | https://conductscience.org/library/papers/19258599 | PubMed |
| 17 | 34649381 | Soluble CD40 Levels in Plasma Are Associated with Cardiovascular Disease and in Carotid Plaques with a Vulnerable Phenotype. | J Stroke | 2021 | https://conductscience.org/library/papers/34649381 | PubMed |
| 18 | 14976003 | CD154/CD40-mediated expression of CD154 in endothelial cells: consequences for endothelial cell-monocyte interaction. | Arterioscler Thromb Vasc Biol | 2004 | https://conductscience.org/library/papers/14976003 | PubMed |
| 19 | 12593727 | A C/T single-nucleotide polymorphism in the region of the CD40 gene is associated with Graves' disease. | Thyroid | 2002 | https://conductscience.org/library/papers/12593727 | PubMed |
| 20 | 12878595 | Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). | J Biol Chem | 2003 | https://conductscience.org/library/papers/12878595 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42835129 | ADAM17 as a proteolytic rheostat linking inflammation, tissue repair, and failure of inflammatory resolution in liver injury and fibrosis. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42835129 | PubMed |
| 42589940 | Soluble CD40 Levels in Rheumatoid Arthritis: Association with Serum Cytokines and Autoantibody Status. | J Clin Med | 2026 | https://conductscience.org/library/papers/42589940 | PubMed |
| 42292487 | The CD40-CD154 axis in transplantation: from immunobiology to therapeutic targeting. | Front Immunol | 2026 | https://conductscience.org/library/papers/42292487 | PubMed |
| 42121886 | Immunomorphological Analysis of the CD40-CD154 Interaction in T Follicular Helper Cell Lymphoma Emphasizes the Significance of the CD40-CD154 Axis in the Disease. | Cells | 2026 | https://conductscience.org/library/papers/42121886 | PubMed |
| 42067655 | Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study. | Nat Cancer | 2026 | https://conductscience.org/library/papers/42067655 | PubMed |
| 40176806 | sCD40 and sCD40L as candidate biomarkers of rheumatic diseases: a systematic review and meta-analysis with meta-regression. | Front Immunol | 2025 | https://conductscience.org/library/papers/40176806 | PubMed |
| 39376569 | Distinct soluble immune checkpoint profiles characterize COVID-19 severity, mortality and SARS-CoV-2 variant infections. | Front Immunol | 2024 | https://conductscience.org/library/papers/39376569 | PubMed |
Genes18
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37566005
GET https://conductscience.org/api/papers/v1/37566005/references?page=2